Samlyn Capital LLC Grows Position in Alder Biopharmaceuticals Inc (ALDR)

Samlyn Capital LLC lifted its position in Alder Biopharmaceuticals Inc (NASDAQ:ALDR) by 47.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 2,818,788 shares of the biopharmaceutical company’s stock after acquiring an additional 904,098 shares during the period. Samlyn Capital LLC’s holdings in Alder Biopharmaceuticals were worth $28,892,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Alder Biopharmaceuticals by 2.3% in the third quarter. Vanguard Group Inc. now owns 5,154,209 shares of the biopharmaceutical company’s stock valued at $85,817,000 after purchasing an additional 115,375 shares during the last quarter. Vanguard Group Inc boosted its holdings in Alder Biopharmaceuticals by 2.3% in the third quarter. Vanguard Group Inc now owns 5,154,209 shares of the biopharmaceutical company’s stock valued at $85,817,000 after purchasing an additional 115,375 shares during the last quarter. BB Biotech AG boosted its holdings in Alder Biopharmaceuticals by 22.1% in the fourth quarter. BB Biotech AG now owns 2,766,008 shares of the biopharmaceutical company’s stock valued at $28,352,000 after purchasing an additional 500,000 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Alder Biopharmaceuticals by 22.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,162,005 shares of the biopharmaceutical company’s stock valued at $11,910,000 after purchasing an additional 215,098 shares during the last quarter. Finally, Brown Advisory Inc. boosted its holdings in Alder Biopharmaceuticals by 4.6% in the third quarter. Brown Advisory Inc. now owns 1,128,303 shares of the biopharmaceutical company’s stock valued at $18,786,000 after purchasing an additional 49,707 shares during the last quarter.

ALDR stock opened at $13.59 on Monday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 14.87 and a current ratio of 14.87. Alder Biopharmaceuticals Inc has a 52-week low of $9.44 and a 52-week high of $20.87. The stock has a market cap of $930.92 million, a PE ratio of -2.79 and a beta of 2.80.

ALDR has been the topic of several recent research reports. Mizuho reaffirmed a “hold” rating and issued a $15.00 price target on shares of Alder Biopharmaceuticals in a report on Wednesday, December 12th. Credit Suisse Group set a $17.00 target price on shares of Alder Biopharmaceuticals and gave the stock a “hold” rating in a research note on Thursday, December 13th. BidaskClub raised shares of Alder Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, January 5th. Zacks Investment Research raised shares of Alder Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Friday, January 11th. Finally, ValuEngine raised shares of Alder Biopharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, January 30th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $20.75.

ILLEGAL ACTIVITY WARNING: “Samlyn Capital LLC Grows Position in Alder Biopharmaceuticals Inc (ALDR)” was originally posted by WKRB News and is owned by of WKRB News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.wkrb13.com/2019/03/18/samlyn-capital-llc-grows-position-in-alder-biopharmaceuticals-inc-aldr.html.

Alder Biopharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.

Further Reading: Certificate of Deposit (CD)

Want to see what other hedge funds are holding ALDR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alder Biopharmaceuticals Inc (NASDAQ:ALDR).

Institutional Ownership by Quarter for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.